Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (300)	9/10/2002 11:22:33 PM
From: scaram(o)uche	Respond to of 3661

Ah, got it. Thanks! You sure do bring good stuff to SI.

To: mopgcw who wrote (300)	9/11/2002 1:38:54 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3661

Continuing the somatokine work. The volume on INSM remains pretty active.<g> It seems to be finding support at the $0.55 level. Will see if it can climb back above $0.65 in order to attempt closing some of the gap above $0.90 They better keep their work on somatokine at a good pace, since there are other better funded companies interested on the field of rhIGF-I/rhIGFBP, not only for diabetes, but for osteoporosis and ALS as well, Roche among them.<g> ncbi.nlm.nih.gov I found the article on the paracrine/autocrine IGF-I-IGFBPs interactions of the peripheral blood mononuclear cells in growth hormone deficient patients interesting. Does any one knows of a similar study in PBMC done in diabetics ? ncbi.nlm.nih.gov Bernard